Jonathan Mow Chief Executive Officer
Jonathan is a life sciences executive with more than 25 years of experience in biotechnology management. He previously served as Chief Business Officer of PhaseBio. Prior to PhaseBio, Jonathan served as Vice President, Business Development for Amylin Pharmaceuticals from 2007 until its sale to Bristol-Myers Squibb in 2012. Jonathan was co-founder and Vice President, Commercial and Business Development of Corus Pharma, Inc., until its acquisition by Gilead Sciences in 2006. Earlier in his career, he led the business development efforts for PathoGenesis Corporation, culminating in the company’s acquisition by Chiron Corporation in 2000. Jonathan has held positions in sales and marketing at Bristol-Myers Squibb, Wyeth / Lederle International and Syntex Laboratories. Jonathan received a BS in Mechanical Engineering from the University of California, Berkeley and an MBA from the Carnegie Mellon University Tepper School of Business.
Susan Arnold, PhD Vice President of Preclinical and CMC
Susan has led all preclinical and assay development activities at PhaseBio since its relocation to Malvern, PA. Prior to PhaseBio, Susan was a Preclinical Project Manager at NuPathe Inc. Earlier in her career, she held positions of increasing responsibility at Viromed Biosafety Laboratories, Targeted Genetics and BioRexis Pharmaceutical. Susan received a BA in biology from Holy Family University and an MS in cell biology and biotechnology and PhD in cell and molecular biology from the University of the Sciences in Philadelphia.
Jim Ballance, PhD Vice President of Research and Scientific Affairs
Jim has more than 25 years of experience in the biopharmaceutical industry, in both small biotechnology and large pharmaceutical companies, specializing in early stage research, product development, cGMP manufacturing, technology transfer and the management of intellectual property. He has led the development of drug products from conception through process development and scale-up to manufacturing, and has extensive business development experience with large pharmaceutical and biotechnology companies. Prior to PhaseBio, Jim was Vice President, Technology Development at BioRexis Pharmaceutical and Director of Business Development at Aventis Behring. Jim invented albumin fusion proteins while at Delta Biotechnology in the United Kingdom, where he was head of research and development. Jim received a BSc in applied biology from the University of Wales and a PhD in fungal molecular genetics from the University of Bristol.
John Lee, MD, PhD Chief Medical Officer
John is a cardiologist with more than 15 years of combined medical practice and biopharmaceutical management experience. Before joining PhaseBio, John served as Vice President & Global Head of the Cardiovascular Center of Excellence at Quintiles Transnational Corp., where he led drug development and product lifecycle management, and established key partnerships to accelerate clinical development and research. Prior to Quintiles, John held several positions at Bristol-Myers Squibb, including Executive Director, Head of Cardiovascular/Metabolic (CV/MET) Therapeutic Area. He also served as Medical Director at Merck & Co. Earlier in his career, John was an attending cardiologist in the University of Pennsylvania’s division of cardiovascular medicine. John received a BA in biological sciences from Harvard University and an MD and PhD in biochemistry from Boston University School of Medicine.
John Sharp Chief Financial Officer
John is a seasoned finance executive with more than 20 years of experience in financial and business planning. Previously, John served as Chief Financial Officer at HUYA Bioscience International, where he played a pivotal role in the company’s strategic direction, including evaluating licensing candidates, tax strategies and all financial activities. Prior to HUYA, John was Chief Financial Officer at Ligand Pharmaceuticals. In this position, he oversaw accounting, treasury, tax and U.S. Securities and Exchange Commission reporting, in addition to financial and operational due diligence on multiple assets and business acquisitions. John also held financial leadership roles at Sequenom, Inc., and Diversa Corporation, and began his career as an auditor at PricewaterhouseCoopers LLP. John received a BS in business administration with an emphasis in accounting from San Diego State University and is a certified public accountant (inactive) in California.
Michael York Vice President of Corporate Development and Commercial Strategy
Michael is a senior life sciences executive with 30 years of commercial, business development and capital markets experience. Most recently, he served as Vice President, Global Business Development and Alliance Management at Orexigen Therapeutics, Inc., where he led global business development activities to license Orexigen assets and manage alliance partners. Previously, Michael was CEO of Senté, Inc., a privately held company and leader in medical skincare products, and a senior advisor for MKO Global Partners, L.P. Earlier in his career, Michael held roles of increasing responsibility at Amylin Pharmaceuticals, including Vice President, Specialty and Rare Disease Unit, and Senior Director, Finance, Investor Relations. Michael also held leadership positions at Santarus, Inc., Amgen and AstraZeneca. Michael received a BA in public administration and economics from San Diego State University and an MBA from the University of Redlands.